Zimmer Biomet Holdings has fallen about 40.9% over the past five years, yet on current checks the stock still screens as undervalued, which raises the question of whether sentiment has swung harder than the fundamentals justify.

• The share price decline of roughly 40.9% over five years signals that investors have been cautious about Zimmer Biomet Holdings despite its established position in medical devices.
• The planned acquisition of Pacira BioSciences' iovera device can support expectations for growth in non opioid pain management, while execution and integration risk around the new asset may influence how much value ultimately flows through to shareholders.
• Zimmer Biomet Holdings currently passes 5 of 6 valuation checks, suggesting that on the broad Simply Wall St framework the stock appears more cheap than expensive overall.

The issue now is whether the current share price of around US$87.47 already reflects the recent news and long term concerns, or if Zimmer Biomet Holdings still offers a margin of safety on valuation grounds.

Zimmer Biomet Holdings delivered -5.6% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Is Zimmer Biomet Holdings Still Cheap on Earnings?

The P/E ratio is a useful way to compare what the market is currently willing to pay for each dollar of earnings at Zimmer Biomet Holdings. At around 22.2x earnings, Zimmer Biomet trades below the Medical Equipment industry average of roughly 25.6x and below the broader peer group average of about 34.0x.

On Simply Wall St’s tailored fair P/E estimate of 27.3x, which takes account of Zimmer Biomet’s industry, size and risk profile, the current multiple also sits at a discount. Despite the recent iovera acquisition announcement, which could influence how investors think about its non opioid pain management portfolio, the market is not pricing the stock at a premium to sector peers on earnings.

On this P/E comparison, Zimmer Biomet stock appears undervalued relative to both its customised fair multiple and the wider industry.

See what the numbers say about this price — find out in our valuation breakdown.

The Zimmer Biomet Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Zimmer Biomet Holdings connect that P/E discount to clear scenarios for the company’s future growth, margins and earnings, spelling out what would need to be true for the stock to be worth materially more or less than today’s price on the Community page. Each one sets out fair value as a thesis about Zimmer Biomet Holdings' business that you can watch over time, rather than as a one off snapshot.

If you have a clear, number driven view on whether Zimmer Biomet Holdings' planned acquisition of Pacira BioSciences' iovera device could justify a different valuation, consider sharing a Narrative on the Community page and setting out the key assumptions behind your case.

This is an opportunity to add your voice to the Zimmer Biomet Holdings discussion and then track how that thesis holds up as new results and updates arrive.

Do you think there's more to the story for Zimmer Biomet Holdings? Head over to our Community to see what others are saying!

The Bottom Line

Zimmer Biomet Holdings currently appears undervalued on earnings multiples, with several valuation checks indicating a discount rather than a premium. That potential upside depends on whether the core business and the planned iovera acquisition can sustain earnings that support even a modest re rating against peers. For investors, the central question is whether today’s lower multiple reflects temporary caution or a lasting concern about execution and integration risk that keeps the stock in value trap territory.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.